Jan Zedenius

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 109 publications

From bench to bedside: the evolving role of iodine in thyroid cancer management.

From bench to bedside: the evolving role of iodine in thyroid cancer management.

Journal: Nature reviews. Endocrinology

Published: May 29, 2026

Genomic Catastrophe Defines the Evolutionary Trajectory of Adrenocortical Carcinoma.

Genomic Catastrophe Defines the Evolutionary Trajectory of Adrenocortical Carcinoma.

Journal: Endocrine pathology

Published: March 28, 2026

Increasing incidence and prevalence of biochemically confirmed primary hyperparathyroidism in Stockholm, 2006-2020.

Increasing incidence and prevalence of biochemically confirmed primary hyperparathyroidism in Stockholm, 2006-2020.

Journal: The Journal of clinical endocrinology and metabolism

Published: January 14, 2026

Preclinical Validation of [177Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials.

Preclinical Validation of [177Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 03, 2025

CD44v6 expression in non-anaplastic thyroid carcinoma: characterization of candidates for targeted therapy.

CD44v6 expression in non-anaplastic thyroid carcinoma: characterization of candidates for targeted therapy.

Journal: Thyroid research

Published: July 02, 2025

Distinguishing neuroendocrine tumor grade 3 from neuroendocrine carcinoma in gastroenteropancreatic high-grade neoplasms.

Distinguishing neuroendocrine tumor grade 3 from neuroendocrine carcinoma in gastroenteropancreatic high-grade neoplasms.

Journal: Endocrine oncology (Bristol, England)

Published: June 25, 2025

Familial Aggregation of Primary Hyperparathyroidism and Malignancy-Nationwide Case-Control and Cohort Study.

Familial Aggregation of Primary Hyperparathyroidism and Malignancy-Nationwide Case-Control and Cohort Study.

Journal: Journal of the Endocrine Society

Published: June 10, 2025

Improving diagnosis in primary aldosteronism using HISTALDO and nodule size metrics.

Improving diagnosis in primary aldosteronism using HISTALDO and nodule size metrics.

Journal: European journal of endocrinology

Published: April 12, 2025

Catching the Silent Culprits: TERT Promoter Mutation Screening of Minimally Invasive Follicular and Oncocytic Thyroid Carcinoma in Clinical Practice.

Catching the Silent Culprits: TERT Promoter Mutation Screening of Minimally Invasive Follicular and Oncocytic Thyroid Carcinoma in Clinical Practice.

Journal: Endocrine pathology

Published: September 30, 2024

Immunotherapy and Tyrosine Kinase Inhibitor as a Bridge to Surgery for Clear Cell Renal Cell Carcinoma Metastases to the Thyroid: A Case Report and Literature Review.

Immunotherapy and Tyrosine Kinase Inhibitor as a Bridge to Surgery for Clear Cell Renal Cell Carcinoma Metastases to the Thyroid: A Case Report and Literature Review.

Journal: Case reports in oncology

Published: July 14, 2024

Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts.

Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts.

Journal: Molecular cancer therapeutics

Published: June 29, 2024

Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer

Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer

Journal: Lakartidningen

Published: May 07, 2024

Showing 1-12 of 109

Last Updated: 09/26/2026